Palisade Bio Inc (PALI)
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker PALI. The company is developing therapies for autoimmune, inflammatory, and fibrotic diseases, with a focus on advancing novel drug candidates through early-stage clinical testing. Its lead program is PALI-2108, a prodrug PDE4 inhibitor being studied in phase 1a/b trials for ulcerative colitis and in a phase 1a trial for fibrostenotic Crohn’s disease. Palisade Bio has also entered into collaboration and licensing arrangements with Giiant Pharma, Inc., the Regents of the University of California, and Newsoara Biopharma Co., Ltd. The company is based in Carlsbad, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PALI
|
$1.41
|
-27.7% Downside
|
Overvalued
|
$10.50
|
438.5% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 25, 2026
|
-14.1x
|
2.7x
|
—
|
331.5 M
|
206.7 M
|
0.0%
|
76.5%
|
32.2
|
—
|
51.4%
|
